Prednisolone reduces hand osteoarthritis pain
A study presented at the European Congress of Rheumatology has shown that low-dose prednisolone is effective in improving pain and function in people with hand osteoarthritis.
Patients with hand osteoarthritis experienced improvements in pain and function with low-dose prednisolone treatment, according to a study presented at the European Congress of Rheumatology in Madrid, Spain (12 June 2019).
Researchers in the Netherlands randomised 92 patients with painful hand osteoarthritis and signs of synovial inflammation to receive prednisolone 10mg daily or placebo. After six weeks, treatment was tapered over a further two weeks, followed by another six weeks without study medication.
Finger pain was assessed using a visual analogue scale, with an average -16.5 point difference in favour of prednisolone over placebo at week six (95% confidence interval; -26.1 to -6.9). Patients treated with prednisolone also showed significant improvements in function and were more likely to be classed as responders using OMERACT-OARSI criteria (72% vs. 33%), a measure of treatment response in terms of pain, function, and patient’s global assessment.
The researchers reported that adverse events were mostly mild and comparable between groups.
Treatment for hand osteoarthritis is generally limited to non-steroidal anti-inflammatory drugs. However, studies suggest that synovial inflammation is often present in hand osteoarthritis and is a main determinant of pain and radiographic disease progression.
“Our study provides evidence that local inflammation is a suitable target for drug treatment in hand osteoarthritis,” said Féline Kroon, lead researcher on the study.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206721
Recommended from Pharmaceutical Press